STADA Arzneimittel AG - Board/Management Information 2016

News Details

Corporate | 11 January 2016 09:55

STADA Arzneimittel AG: Appointment of Dr. Matthias Wiedenfels extended

DGAP-News: STADA Arzneimittel AG / Key word(s): Contract

2016-01-11 / 09:55

The issuer is solely responsible for the content of this announcement.

Press release

STADA: Appointment of Dr. Matthias Wiedenfels extended

Bad Vilbel, January 11, 2016 – On January 8, 2016, the Supervisory Board of STADA Arzneimittel AG extended the appointment of Dr. Matthias Wiedenfels as Chief Business Development & Central Services Officer by four years until December 31, 2020. Dr. Wiedenfels has been a Member of STADA’s Executive Board since 2013. His previous contract would have ended on December 31, 2016. Within the Executive Board, Dr. Wiedenfels is responsible for the areas of Business Development, Portfolio Management, Human Resources, Legal, IP/Patents, Compliance (including Export Control), Risk Management, as well as for Quality Assurance and Quality Control.

“I’m very pleased about this repeated sign of confidence and about the opportunity to continue the successful cooperation with my two colleagues in the Executive Board in the coming years. In addition to the challenges that lie ahead of us, we are also facing some great opportunities, which we will take advantage of to pursue STADA’s sustainable development goals. This includes the further acceleration of the internationalization strategy through value-enhancing acquisitions”, says Dr. Wiedenfels about the plans in connection with the extension of his contract.

The extension of the appointment of Dr. Wiedenfels and last year’s extension of the appointment of the Chairman of the Executive Board and the Chief Financial Officer ensure the continued stability in the Executive Board of STADA Arzneimittel AG. The STADA Executive Board continues to consist of Hartmut Retzlaff, Chairman, Helmut Kraft, Chief Financial Officer, and Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer.

Additional information for analysts:

STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]

Or visit us in the Internet at http://www.stada.com .

2016-01-11 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de


Language:	English
Company:	STADA Arzneimittel AG
	Stadastraße 2-18
	61118 Bad Vilbel
	Germany
Phone:	+49 (0)6101 603- 113
Fax:	+49 (0)6101 603- 506
E-mail:	[email protected]
Internet:	www.stada.de
ISIN:	DE0007251803, DE0007251845,
WKN:	725180, 725184,
Indices:	MDAX
Listed:	Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart